Loading
Breast Cancer Treatment Studies / HER2/EGFR in Cancer Research / Advanced Breast Cancer Therapies · Journal article
ESMO Open · August 7, 2026
Well-designed and adequately powered for the question it asks.
This review synthesizes evidence that HER2DX, a genomic-clinical test integrating tumor biology with clinical variables, provides independent prognostic and predictive information in early-stage HER2-positive breast cancer. Large meta-analyses and prospective studies support its association with survival outcomes and pathological response, suggesting potential clinical utility for treatment intensity tailoring, though implementation in routine practice requires further prospective evaluation.
Narrative review synthesizing meta-analyses and prospective trial evidence. Literature addressing HER2DX performance in early-stage HER2-positive breast cancer; stage I-III patients included in referenced studies. Intervention: HER2DX genomic-clinical test generating prognostic risk score, pCR score, and ERBB2 mRNA expression score. Compared with: Standard clinicopathological assessment (tumor size, nodal status). International meta-analyses; prospective studies in US (ECOG-ACRIN EA1181) and Spain.
HER2DX risk score shows independent association with survival outcomes beyond standard clinicopathological factors in large international meta-analyses HER2DX pCR score demonstrates independent association with pathologically documented response beyond standard factors Translational studies show HER2DX captures complementary biological features including hormone receptor signaling, proliferation, HER2 pathway activation, and immune infiltration
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians considering HER2DX should recognize its demonstrated independent prognostic and predictive value for individualized treatment intensity decisions in HER2-positive disease, though prospective effectiveness data in routine practice remain emerging.
Meta-analyses demonstrate independent prognostic and predictive associations of HER2DX scores with survival and pathological response beyond standard factors, supported by translational validation and prospective trial data.
As stated by the source record.
Clinicians considering HER2DX should recognize its demonstrated independent prognostic and predictive value for individualized treatment intensity decisions in HER2-positive disease, though prospective effectiveness data in routine practice remain emerging.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Therapies targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer have substantially improved outcomes. Nevertheless, marked biological and clinical heterogeneity continue to drive variability in prognosis and treatment sensitivity in early-stage disease. While contemporary guidelines provide broad management frameworks, uncertainty remains when tailoring treatment intensity to individual patients. HER2DX is a genomic-clinical test developed to support individualized decision-making in stage I-III HER2-positive breast cancer by integrating tumor biology with key clinical variables, including tumor size and nodal status. The assay generates three clinically relevant outputs: a prognostic relapse risk score, a pathological complete response (pCR) score, and an ERBB2 messenger RNA expression score. Since its original development, a substantial body of new evidence has emerged. Large international individual-patient-level meta-analyses have demonstrated independent associations of the HER2DX risk score with survival outcomes and of the pCR score with pathologically documented response beyond standard clinicopathological factors. Translational studies further show that HER2DX captures complementary biological features, such as hormone receptor signaling, proliferation, HER2 pathway activation, and immune infiltration and organization, that are not fully reflected by conventional pathology. Prospective evaluations, including prespecified analyses from the ECOG-ACRIN EA1181 CompassHER2 pCR trial and a multicenter real-world decision-impact study in Spain, provide additional evidence regarding the potential clinical application of HER2DX in both neoadjuvant and adjuvant settings. This updated review synthesizes current evidence and discusses practical, scenario-based considerations for integrating HER2DX into routine clinical practice to help optimize treatment intensity in early-stage HER2-positive breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.